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Summary In December 2006, three human specimens were received that were
suspected positive for inﬂuenza A(H5N1). The specimens were tested using real
time PCR. And the presence of A(H5N1) virus was conﬁrmed in 2 patients (16F and
26M), The NA sequence from A(H5N1) positive specimens collected before and after
antiviral therapy revealed a mutation (N294S) (N295S according to N1 numbering),A(H5N1);
Egypt
previously associated with resistance to oseltamivir. When tested with NA inhibition
assays, the two N294S viruses from Egypt exhibited from 57 to 138-fold reduction in
susceptibility to oseltamivir, depending on the assay. To our knowledge, this is the
ﬁrst time oseltamivir resistance has been detected in A(H5N1) infecting a human
prior to treatment.
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ntroductionvian inﬂuenza A(H5N1) virus is by far one of
he most important public health concerns world-
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Rseltamivir resistance mutation N294S in human in
ide. It has sparked fears based on its potential
o serve as the source of the next pandemic
train of inﬂuenza. A(H5N1) has been evident in
outh East Asia since 2003. Since late 2005, the
irus has spread to many countries in Europe, Asia
nd Africa [1]. At present, there is no commer-
ial vaccine for A(H5N1) for humans. Oseltamivir
s the most recommended antiviral for treatment
f conﬁrmed or strongly suspected infections of
(H5N1) [2]. As with any antiviral drug, emer-
ence of a pandemic strain or a strain that is
esistant to oseltamivir is a concern. Previously,
seltamivir resistance was detected in persons
ndergoing treatment for inﬂuenza A and B infec-
ions (Reviewed by Aoki et al. Antiviral Therapy,
2:603-16, 2007) [3], with the highest frequency
f resistance seen in young children after initiation
f oseltamivir treatment. A number of amino acid
hanges in the neuraminidase (NA) were respon-
ible for variable degrees of resistance, when
ssessed in NA inhibition assays. In the 2007—2008
eason, the emergence of wide spread oseltamivir-
esistant A(H1N1) viruses carrying H274Y mutation
as detected in several countries, with the high-
st frequency of resistance (up to 67%) seen in
urope [4]. A lack of apparent correlation between
he prevalence of resistance in A(H1N1) viruses
nd in-country use of oseltamivir raises concerns
egarding uncompromised ﬁtness of oseltamivir-
esistant viruses. In the United States during the
007—2008 season 12.3% of H1N1 inﬂuenza viruses
emonstrated resistance to oseltamivir and early
urveillance during the 2008—2009 season reports
8.5% resistance of H1N1 isolates with no clini-
al or demographic difference between cases [5].
n 2008, 100% oseltamivir resistance was reported
rom 92 viruses isolated in South Africa [6]. As
f 18 March 2009 the World Health Organiza-
ion reports widespread oseltamivir resistance in
0 countries from all regions [7]. Emergence of
esistant A(H5N1) variants with H274Y mutation
n the NA was detected in patients in Vietnam
ho were treated with oseltamivir for A(H5N1)
nfection [8,9]. These recent ﬁndings highlight the
mportance of close monitoring of neuraminidase
nhibitor (NI) susceptibility among A(H5N1) viruses.
The ﬁrst report of A(H5N1) virus introduction
n Egypt occurred in poultry and was conﬁrmed
n February 2006. Poultry in Egypt was infected
ith the virus similar to the Qinghai strain ﬁrst
etected in western China in 2005 [1]. Human
nﬂuenza A(H5N1) infection was ﬁrst identiﬁed in
gypt in March and April 2006 and was mainly due to
xposure to/or handling sick household poultry. No
urther cases of human infections were identiﬁed
ntil October 2006. From March 2006 to February
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007 Egypt reported 22 human cases of inﬂuenza
(H5N1) with 13 deaths. All cases were treated with
seltamivir using WHO guidelines.
In December 2006, three deadly human cases of
(H5N1) were detected in a family in the Gharbiya
overnorate (Nile Delta region, Lower Egypt). The
ases included 2 females (age 35 and 16) and 1
ale (age 26) from an extended family living in the
ile Delta. All cases participated in the slaughter
f household ducks on December 13 and developed
nﬂuenza like illness between December 15 and 19.
n December 21, a throat swab was collected from
ach case before beginning oseltamivir treatment.
second throat swab was collected on December
3rd. All 3 cases died from pneumonia compli-
ated by adult respiratory distress syndrome. The
iruses isolated from two of those cases are the
ubject of the present study. As a WHO reference
aboratory for avian inﬂuenza, NAMRU-3 conﬁrms
uman cases of avian inﬂuenza. Monitoring genetic
hanges in the HA and NA genes of viruses isolated
n Egypt is important to detect emerging possible
andemic strains or antiviral resistance. In Egypt,
total of 59 human cases with 23 fatalities have
een reported up to March 2009 (WHO update; 23
arch 2009).
aterials and methods
iruses and RNA isolation
re-treatment throat swab samples were received
rom the Central Public Health Laboratory (CPHL)
f the Egyptian Ministry of Health in viral trans-
ort medium. RNA extracts were received from
amples collected both before and after initiation
f treatment with oseltamivir. Viral RNA extrac-
ion was performed using the Qiagen Viral RNA
ini kit (Qiagen Inc., Valencia, CA) according to
he manufacturer procedure. CPHL initial positive
esults were conﬁrmed at NAMRU-3 using the spe-
iﬁc real time PCR method for the detection of
nﬂuenza A matrix and H5 gene according to Spack-
an et al. [10]. N1-gene speciﬁc real time PCR was
erformed according to Payungyoung et al., 2005
11]. Virus was isolated from both pre-treatment
amples.
T-PCR and sequencingCR ampliﬁcation of overlapping fragments from
ach HA and NA gene was performed using
n-house designed speciﬁc primers (primers avail-
ble upon request). Sequencing of the PCR
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amplicons was performed using the BigDye Termi-
nator cycle sequencing reaction mix Version 3.1
(Applied Biosystems, Foster city, CA). Sequences
were edited using the Sequencher software Ver-
sion 4.6 (Gene Codes Corporation, MI, USA)
and analyzed using Bioedit [12] and MEGA3.1
software [13].
Neuraminidase inhibition (NAI) assays
Compounds
Zanamivir (GG167) was provided, courtesy of
GlaxoWellcome Research and Development
(Stevenage, United Kingdom); oseltamivir carboxy-
late (GS4071) was provided by Roche Laboratories,
Inc. (Nutley, NJ); peramivir was provided by
BioCryst, Inc. (Birmingham, AL).
Phenotypic drug susceptibility testing
Viruses isolated (without further passage) and
RNA extracts from pre-treatment collected sam-
ples were shipped to the U.S. Centers for Disease
Control and Prevention (CDC) for further test-
ing. Phenotypic testing was performed on both
isolates using the chemiluminescent assay and
on A/Egypt/14725-NAMRU3/2006 using ﬂuorescent
and colorimetric assays in the BSL-3 laboratory of
the Inﬂuenza Division at CDC, Atlanta, Georgia,
USA, as previously described [14—16].
Phylogenetic analysis was performed using the
Molecular Evolutionary Genetics Analysis (MEGA
3.1) [13].
Results
Two of the three Gharbiya cases were conﬁrmed
by A(H5N1)-speciﬁc real time PCR at NAMRU-
3. Alignment of their NA amino acid sequences
revealed a mutation N294S (numbering according
to N2) previously reported to be associated with
oseltamivir resistance in N1 and N2 subtypes of
inﬂuenza A viruses [9,17]. The N294S mutation was
observed in samples collected pre and post treat-
ment in both conﬁrmed cases as well as in the
viruses isolated from the pre-treatment sample.
Prior to initiating phenotypic testing CDC con-
ﬁrmed presence of N294Smutation in the submitted
samples. Initially, the oseltamivir-susceptibility of
the two inﬂuenza A(H5N1) viruses was assessed
using the chemiluminescent NA inhibition assay.
The IC50 values were similar for both viruses and
exhibited a 57-fold increase (17 nM vs. 0.3 nM) com-
pared to those of the A/Turkey/15/2006 (H5N1)
virus, a sensitive control from the same genetic
h
t
u
A
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lade (2.2). To conﬁrm the decreased oseltamivir-
usceptibility, A/Egypt/14725-NAMRU3/2006 virus
as then tested using the ﬂuorescent and colori-
etric NA inhibition assays which utilize different
nzyme substrates. The results of these two assays
ndicated even greater reduction (93-fold and
38-fold, respectively) in oseltamivir susceptibility
Table 1).
The IC50 value for the wild type virus,
/Turkey/15/2006 (H5N1), varied from 0.3—3.1 nM,
epending on the enzyme substrate used in the
est, which is a known phenomenon [15]. The
ifference was greater for the A/Egypt/14725-
AMRU3/2006 virus, ranging from 17.0—426.6 nM
Table 1).
Because of uncertainty regarding the predic-
ive value of in vitro NI assays, we compared
he IC50 values to those of the human refer-
nce virus, A/Texas/36/1991 (H1N1) wild type and
ith the oseltamivir resistance-conferring muta-
ion H274Y [18]. The wild type A/Texas/36/1991
H1N1) virus exhibited IC50s similar to those
f the sensitive control A(H5N1) virus from
lade 2.2., A/Turkey/15/2006 (Table 1). The
gypt/14725-NAMRU3/2006 showed IC50s approxi-
ately 10-fold lower compared to those of the
seltamivir-resistant A/Texas/36/1991 using the
hemiluminescent and ﬂuorescent assays. Of note,
he difference was less than 2-fold (426.6 nM vs.
19.6 nM) using the colorimetric assay, which uti-
izes a large and natural substrate (fetuin).
Furthermore, the susceptibilities of the
/Egypt/14725-NAMRU3/2006 virus and the con-
rol viruses were also assessed against other NIs,
anamivir and peramivir. Based on the IC50 values
btained using chemiluminescent and ﬂuorescent
ssays, the susceptibility of the A/Egypt/14725-
AMRU3/2006 to either zanamivir or peramivir was
ot substantially altered (2—4-fold increase). How-
ver, a 27- and 130-fold reduction in susceptibility
o these drugs, respectively, was detected using
he colorimetric assay (Table 1).
The HA gene from the two positive cases
evealed newly acquired amino acid changes that
ere not seen in March—April 2006 cases, mainly
230I and V223I. M230I is a mammalian poly-
orphism adjacent to a receptor binding site.
hylogenetic analysis of the HA and NA genes
Figs. 1 and 2) revealed that these two viruses
elong to the ‘Qinghai-like’ group of viruses and
luster with the previous A(H5N1) strains from
uman or avian species from Egypt. Furthermore,
he phylogeny, supported with high bootstrap val-
es, suggests at least two main subclusters of
(H5N1) viruses co-circulating in Egypt, one in
pper Egypt and another in the Delta region. The
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esistant strains belong to the subcluster from
ower Egypt (Nile Delta region) (Fig. 2).
iscussion
ince 1997, avian inﬂuenza A(H5N1) virus caused
ver 412 human infections with more than half of
hese cases being fatal (n = 256). In Egypt, the num-
er of human infections caused by A(H5N1) virus
eached 59 with 23 deaths (WHO updated report of
3 March, 2009; http://www.who.int/csr/disease/
vian inﬂuenza/country/cases table 2009 03 23a/
n/index.html). Currently, there are four FDA
pproved drugs for inﬂuenza belonging to two
lasses, M2 blockers and NA inhibitors. The useful-
ess of M2 blockers (amantadine and rimantadine)
as diminished in recent years due to emergence
f cross-resistant inﬂuenza A viruses of H3N2, H1N1
nd H5N1 antigenic subtypes [19—24]. For reasons
hat are not yet known, oseltamivir resistant
1N1 now appears to be widely circulating during
he 2008—2009 season. The WHO recommends
sing oseltamivir at 75mg twice daily [2] to treat
(H5N1) infections and supports stockpiling in
dvance of a pandemic. The necessity of inhaled
elivery hinders the use of zanamivir. Another NI,
eramivir, is undergoing clinical evaluations at this
ime [25]. Because treatment options of inﬂuenza
nfections are limited, monitoring of susceptibility
o existing antiviral drugs is critical, especially
gainst oseltamivir, which is the current ﬁrst line
f defense against highly pathogenic A(H5N1)
iruses. Data on molecular markers of oseltamivir-
esistance (acquired and spontaneous) in A(H5N1)
iruses is insufﬁcient, which emphasizes the need
or investigating the changes in drug-targeted
olecule (NA) of viruses recovered from treated
s well as untreated patients. Emergence of virus
ariants carrying H274Y mutation that confers a
igh level of oseltamivir-resistance was previously
etected in viruses recovered from three patients
n Vietnam, treated with oseltamivir for A(H5N1)
irus infections (clade 1 genetic group) [8,9].
oreover, virus carrying mutation N294S was also
etected in one of the patients mentioned above.
n clade 1 genetic background, the N294S muta-
ion conferred a moderate oseltamivir-resistance
7.1—12.5 nM), when assessment was done using
he ﬂuorescent NA inhibition assay [6].
In the present study the mutation N294S wasetected in the A(H5N1) viruses recovered from two
atients in Egypt who did not survive the infec-
ion. It is uncertain whether N294S mutation by
tself was responsible for treatment failure. To be
ffective, treatment with oseltamivir needs to be
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nza
6 st
gypt
[
t
e
H
a
t
w
(
t
t
p
(
o
f
o
cFigure 1 Neighbor-joining phylogenetic tree of the inﬂue
from clade 2.1 (Indonesia) and Clade 0 (Guangdong 199
viruses are clearly co-circulating in Egypt, one in Upper E
initiated during the ﬁrst two days after symptoms
onset, which is not usually possible [26]. In contrast
to the previous reports from the Vietnamese cases,
the resistance-conferring mutation was detected
before and after oseltamivir-treatment, indicat-
ing its spontaneous nature. There is signiﬁcant
divergence in the NA sequences and structures
among avian A(H5N1) viruses [27] which may have
signiﬁcant implications for antiviral susceptibility,
especially for oseltamivir [28]. This is the ﬁrst
report demonstrating the effects of N294S muta-
tion on susceptibility of A(H5N1) viruses from clade
2.2 to oseltamivir and other NA inhibitors.
Testing with all three NA assays yielded increased
IC50 values against oseltamivir. Noteworthy, the
IC50 value for the A/Egypt/14725-NAMRU3/2006
virus assessed using the colorimetric assay was
greater than those obtained in the small-substrate
assays (427 nM equals ∼142 ng/ml) and was close to
observed plasma concentration of oseltamivir car-
boxylate (median Cmin = 167 nM; Cmax = 332 ng/ml)
m
i
i
bA virus (H5N1) HA gene of strains from Egypt with strains
rain). Two distinct phylogenetic subclusters of A(H5N1)
and another in the Delta region.
29] achieved using the recommended oseltamivir
reatment regimen [2]. The IC50 value (719.6 nM
quals ∼240 ng/mL) of the oseltamivir-selected
274Y mutant assessed using the fetuin-based
ssay was within the range of plasma concentra-
ions of oseltamivir carboxylate (167—332 ng/mL);
hereas those plasma concentrations substantially
∼140-fold) exceeded the IC50 values of both wild
ype viruses. Regardless of the substrate utilized,
he IC50 values determined against zanamivir and
eramivir for the A/Egypt/14725-NAMRU3/2006
N294S) virus were much lower than those against
seltamivir.
Although no poultry were available for testing
rom the house of the studied cases, existence
f resistance mutation prior to treatment in both
ases strongly suggests its spontaneous nature and
ay have existed in other viruses infecting poultry
n Gharbiya governorate in Egypt. Since oseltamivir
s themost widely stockpiled drug for a future possi-
le inﬂuenza virus pandemic, based on the ﬁndings
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utliers.
f this study, the development and inclusion of
lternative inﬂuenza A virus antiviral drugs in the
reatment strategy need to be considered.
To our knowledge, this is the ﬁrst report where
seltamivir resistant A(H5N1) viruses were recov-
red from humans prior to initiation of treatment.
o further oseltamivir resistant isolates have been
dentiﬁed, however, A(H5N1) continues to circulate
n Egypt and other countries. Oseltamivir resis-
ance in H1N1 resulting from H274Y mutation is
ow widespread. Although the clinical relevance
f oseltamivir resistance has not been determined,
ur ﬁndings emphasize the necessity of close mon-
toring of A(H5N1) viruses for the emergence of
esistance.
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